Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease
Dolby (Netherlands) · Black Hills Center for American Indian Health · +4 more institutions
Abstract
BACKGROUND: Ticagrelor is the first reversibly binding oral P2Y(12) receptor antagonist. This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using the PLATO (PLATelet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel. METHODS AND RESULTS: In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery disease who were taking aspirin therapy (75 to 100 mg/d) received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks. Greater IPA (20 micromol/L ADP, final extent) occurred with…
Citation impact
- FWCI
- 51.26
- Percentile
- 100%
- References
- 16
Authors
16- PAPaul A. GurbelCorresponding
Dolby (Netherlands), Black Hills Center for American Indian Health, AstraZeneca (United States), Christ Hospital, Drexel University, University of Sheffield
- KPKevin P. Bliden
Dolby (Netherlands), Black Hills Center for American Indian Health, AstraZeneca (United States), Christ Hospital, Drexel University, University of Sheffield
- KBKathleen Butler
Dolby (Netherlands), Black Hills Center for American Indian Health, AstraZeneca (United States), Christ Hospital, Drexel University, University of Sheffield
- USUdaya S. Tantry
Dolby (Netherlands), Black Hills Center for American Indian Health, AstraZeneca (United States), Christ Hospital, Drexel University, University of Sheffield
- TGTania Gesheff
Dolby (Netherlands), Black Hills Center for American Indian Health, AstraZeneca (United States), Christ Hospital, Drexel University, University of Sheffield
Topics & keywords
- Medicine
- Ticagrelor
- Clopidogrel
- Coronary artery disease
- Cardiology
- Internal medicine
- Double blind
- Randomized controlled trial
- Good health and well-being